{"id":"W4205646635","doi":"10.1158/1078-0432.ccr-21-3530","title":"Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial","year":2022,"lang":"en","type":"article","venue":"Clinical Cancer Research","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":25,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Loxo Oncology; Eli Lilly Japan; Chugai Pharmaceutical; EMD Serono; Genentech; Ignyta; Eli Lilly and Company; Ono Pharmaceutical; Sanofi; Kyowa Hakko Kirin; Teijin Pharma; Daiichi-Sankyo; Halozyme; Mirati Therapeutics; National Center for Advancing Translational Sciences; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Pfizer; Symphogen; Bristol-Myers Squibb; AstraZeneca; Shire; Taiho Pharmaceutical; F. Hoffmann-La Roche; Novartis Pharma; AbbVie; Spectrum Pharmaceuticals; Medtronic Japan; Amgen; Bayer","keywords":"Osimertinib; Adjuvant; Lung cancer; Quality of life (healthcare); Clinical trial; Phases of clinical research; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001682401,0.0007523868,0.001430866,0.0001600659,0.0002880281,0.0009306911,0.0004053118,0.0007864666,0.001163347],"category_scores_gemma":[0.0009409735,0.0002239944,0.001423025,0.0002654289,0.0004192431,0.0004418534,0.0002359506,0.001702542,0.0002305168],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004403652,"about_ca_system_score_gemma":0.0005331697,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005614595,"about_ca_topic_score_gemma":0.001603224,"domain_scores_codex":[0.9995396,0.0002656582,0.00002917265,0.00005161751,0.00004986478,0.00006419199],"domain_scores_gemma":[0.9995337,0.0001004248,0.0001556957,0.00002932433,0.00003356534,0.0001472767],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.8272653,0.007744207,0.09627789,0.00125325,0.004775424,0.0002084317,0.0001785916,0.001420396,0.006770815,0.0002112626,0.003826581,0.05006788],"study_design_scores_gemma":[0.4909311,0.1862777,0.3064416,0.0002679493,0.005536214,0.000379654,0.0002036686,0.002145134,0.002181258,0.0003776217,0.005192832,0.00006522489],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928975,0.005124331,0.00009202497,0.0003119064,0.0001210852,0.0002671625,0.0004214382,0.000009814209,0.0007546396],"genre_scores_gemma":[0.9961404,0.001280972,0.0001924782,0.000400751,0.0001681857,0.0003474733,0.001005098,0.000002755543,0.0004619122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001682401,"threshold_uncertainty_score":0.008897483,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1696499595498575,"score_gpt":0.5233249970360567,"score_spread":0.3536750374861992,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}